98140-03-5

Basic information

• Product Name: 6-chloro-N4-ethylpyrimidine-4,5-diamine
• Synonyms: 6-chloro-N4-ethylpyrimidine-4,5-diamine;6-CHLORO-N4-ETHYL-4,5-PYRIMIDINEDIAMINE;AKOS A0602-0610;6-CHLORO-4-N-ETHYLPYRIMIDINE-4,5-DIAMINE
• CAS NO: 98140-03-5
• Molecular Formula: C₆H₉ClN₄
• Molecular Weight: 172.61546
• Mol File: 98140-03-5.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-chloro-N4-ethylpyrimidine-4,5-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-N4-ethylpyrimidine-4,5-diamine(98140-03-5)
• EPA Substance Registry System: 6-chloro-N4-ethylpyrimidine-4,5-diamine(98140-03-5)

Safety Data

• Hazardous Substances Data: 98140-03-5(Hazardous Substances Data)

Usage

General Description

6-chloro-N4-ethylpyrimidine-4,5-diamine is a chemical compound with the molecular formula C7H10ClN5. It is a member of the pyrimidine family, which is a heterocyclic organic compound that contains two nitrogen atoms in a six-membered ring. This specific compound is a chloroethyl derivative of pyrimidine-4,5-diamine and is often used as a building block in the synthesis of pharmaceuticals and agrochemicals. It has potential uses in the development of antiviral and anticancer drugs, as well as in the production of herbicides and pesticides. Additionally, it may have other industrial applications due to its unique chemical properties and structure.

Upstream product

• 5413-85-4 5-amino-4,6-dichloropyridimine 
• 75-04-7 ethylamine 
• 25710-24-1 4-Chlor-6-aethylamino-5-nitropyrimidin 
• 557-66-4 ethanamine hydrochloride 
• 4316-98-7 6-chloro-4,5-diaminopyrimidine 

Downstream Products

• 5462-86-2 6-chloro-9-ethyl-9H-purine 
• 101080-16-4 N⁴-ethyl-pyrimidine-4,5-diyldiamine 
• 492464-38-7 6-ethoxy-8-methyl-9-(ethyl)-9H-purine 
• 5427-23-6 9-Ethylpurine 
• 5427-20-3 9-Ethyl-9H-purin-6(1H)-thion 
• 7252-00-8 6-methylthio-9-ethylpurine 
• 5427-22-5 N⁶,N⁶-Dimethyl-9-ethyladenine 
• 868163-66-0 6-chloro-9-ethyl-8-phenyl-9H-purine 
• 1610711-25-5 N-(3-{[9-ethyl-8-(2-methylpyrimidin-5-yl)-9H-purin-6-yl]amino}cyclohexyl)-1,3-oxazole-4-carboxamide 
• 1610706-31-4 N-((1S,3S)-3-{[9-ethyl-8-(2-methylpyrimidin-5-yl)-9H-purin-6-yl]amino}cyclohexyl)-1,3-oxazole-4-carboxamide 
• 1610706-30-3 N-((1R,3R)-3-{[9-ethyl-8-(2-methylpyrimidin-5-yl)-9H-purin-6-yl]amino}cyclohexyl)-1,3-oxazole-4-carboxamide 
• 1610703-98-4 9-ethyl-8-(2-methylpyrimidin-5-yl)-N-[(3S)-1-(phenylacetyl)pyrrolidin-3-yl]-9H-purin-6-amine 

Relevant articles and documents

Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings

Introduction: There is considerable interest in the development of selective PI3Kδ inhibitors for the treatment of inflammatory diseases and haematological cancers. Merck has no previous filings in this field but licensed Exelixis' programme, including its lead compound XL-499, in December 2011.Areas covered: Both applications claim novel 9-alkyl-6,8-disubstituted purine derivatives as selective δ inhibitors for the treatment of asthma, obstructive airways disease, arthritis and cancer. The two applications differ in the range of exemplified substituents, the first focusing on 8-heteroaryl substituted purines, the second on 8-aminopurine derivatives. Many of the exemplified compounds have IC50 values a number having sub-nanomolar potency.Expert Opinion: The compounds appear to be XL-499 derivatives, some of which are more potent than XL-499. The compounds claimed by Merck are some of the most potent PI3Kδ inhibitors yet described but it is unclear whether a development compound has been identified.

Design, Synthesis, and Evaluation of Novel Isothiazole-Purines as a Pyruvate Kinase-Based Fungicidal Lead Compound

Target identification is one of the most important bases for novel pesticide development; pyruvate kinase (PK) was discovered as a potent fungicide target in our previous studies. To continue the PK-based fungicide development, novel isothiazole-purine derivatives were rationally designed and synthesized. Bioassay results showed that compound 5ai displayed excellent in vitro activity against Rhizoctonia solani with an EC50 of 1.5 μg/mL, which was superior to those of positive controls diflumetorim with its EC50 of 19.8 μg/mL and PK-based lead YZK-C22 with its EC50 of 4.2 μg/mL. Compounds 3b (5.2 μg/mL) and 3c (4.5 μg/mL) displayed better activities against Gibberella zeae with their EC50s falling between 4.0 and 5.5 μg/mL, while YZK-C22 showed an EC50 of 6.4 μg/mL. In addition, 5ah exhibited promising in vivo activity against Erysiphe graminis and Puccinia sorghi Schw. with 100% efficacy at 10 μg/mL and 90% efficacy at 2 μg/mL against P. sorghi Schw. Compound 5ai showed good PK inhibitory activity with an IC50 of 38.8 μmol/L, and it was well docked into the active site of the target enzyme PK, which was slightly more active than YZK-C22 with its IC50 of 42.4 μmol/L. Our studies discovered that isothiazole-purines were PK-based fungicidal leads deserving of further study.

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

The instant invention provides compounds of formula (I) which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.